{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:22Z","timestamp":1783075942777,"version":"3.54.6"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Science Centre, Krak\u00f3w, Poland","award":["2011\/01\/B\/NZ4\/04859"],"award-info":[{"award-number":["2011\/01\/B\/NZ4\/04859"]}]},{"name":"Institute of Pharmacology, PAS, Krak\u00f3w, Poland"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.bcp.2014.05.005","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T15:16:10Z","timestamp":1400253370000},"page":"188-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application"],"prefix":"10.1016","volume":"90","author":[{"given":"Jacek","family":"W\u00f3jcikowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Basi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142adys\u0142awa A.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2014.05.005_bib0005","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1185\/030079904X12708","article-title":"Focus on levomepromazine","volume":"20","author":"Green","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bcp.2014.05.005_bib0010","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00228-010-0839-9","article-title":"Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up","volume":"66","author":"Gjerden","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-684X-12-2","article-title":"Evidence for the use of levomepromazine for symptom control in the palliative care setting: a systematic review","volume":"12","author":"Dietz","year":"2013","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.bcp.2014.05.005_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0014-2999(86)90793-4","article-title":"Phenothiazine drugs metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding","volume":"125","author":"Hals","year":"1986","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0447.1993.tb03391.x","article-title":"Levomepromazine receptor binding profile in human brain \u2013 implications for treatment-resistant schizophrenia","volume":"87","author":"Lal","year":"1993","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.bcp.2014.05.005_bib0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0026-895X(25)14601-4","article-title":"Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation","volume":"21","author":"Dahl","year":"1982","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0024-3205(88)90519-X","article-title":"Muscarinic, cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites","volume":"43","author":"Hals","year":"1988","journal-title":"Life Sci"},{"key":"10.1016\/j.bcp.2014.05.005_bib0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00432672","article-title":"Binding affinity of levomepromazine and two of its major metabolites to central dopamine and \u03b1-adrenergic receptors in the rat","volume":"74","author":"Dahl","year":"1981","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2014.05.005_bib0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-642-25761-2_4","article-title":"Serotonergic mechanisms as targets for existing and novel antipsychotics","volume":"212","author":"Meltzer","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.psychres.2012.01.009","article-title":"Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal","volume":"198","author":"Benyamina","year":"2012","journal-title":"Psychiatr Res"},{"key":"10.1016\/j.bcp.2014.05.005_bib0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/schbul\/sbr174","article-title":"Levomepromazine for schizophrenia","volume":"38","author":"Sivaraman","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bcp.2014.05.005_bib0060","first-page":"271","article-title":"Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial","volume":"31","author":"Lal","year":"2006","journal-title":"J Psychiatr Neurosci"},{"key":"10.1016\/j.bcp.2014.05.005_bib0065","first-page":"1283","article-title":"Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action","volume":"19","author":"Tsukamoto","year":"1984","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.bcp.2014.05.005_bib0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-0447.1995.tb05940.x","article-title":"Long-term treatment of mood disorders in schizophrenia","volume":"388","author":"Azorin","year":"1995","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.bcp.2014.05.005_bib0075","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00520-004-0768-1","article-title":"An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer","volume":"13","author":"Kennett","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bcp.2014.05.005_bib0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF03192290","article-title":"Metabolism of levomepromazine in man","volume":"20","author":"Hals","year":"1995","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bcp.2014.05.005_bib0085","series-title":"Progress in drug metabolism","first-page":"111","article-title":"Metabolism and pharmacokinetics of antipsychotic drugs","author":"J\u00f8rgensen","year":"1986"},{"key":"10.1016\/j.bcp.2014.05.005_bib0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0090-9556(25)07838-9","article-title":"Identification of O-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man","volume":"10","author":"Johnsen","year":"1982","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2014.05.005_bib0095","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/792456","article-title":"Comparative cytochrome P450 in vitro inhibition by atypical antipsychotic drugs","author":"Gervasini","year":"2013","journal-title":"ISRM Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00007691-199302000-00003","article-title":"Citalopram: interaction studies with levomepromazine, imipramine, and lithium","volume":"15","author":"Gram","year":"1993","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bcp.2014.05.005_bib0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF00626371","article-title":"Debrisoquine oxidation phenotype during neuroleptic monotherapy","volume":"41","author":"Spina","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0110","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0022-3565(25)21837-7","article-title":"A study of the kinetics of chlorpromazine sulfoxide by a specific radioimmunoassay after a single oral dose of chlorpromazine in healthy volunteers","volume":"3","author":"Yeung","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2014.05.005_bib0115","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0040-4039(01)82479-5","article-title":"2,2,2-Trichloroethyl-chloroformate: a general reagent for demethylation of tertiary methylamine","volume":"14","author":"Montzka","year":"1974","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bcp.2014.05.005_bib0120","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bcp.2010.06.045","article-title":"Main contribution of cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver\u2013a comparison with other phenothiazines","volume":"80","author":"W\u00f3jcikowski","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0125","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjp.0705195","article-title":"Contribution of human cytochrome P-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine","volume":"138","author":"W\u00f3jcikowski","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0924-977X(03)00105-6","article-title":"The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes","volume":"14","author":"W\u00f3jcikowski","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/dmd.105.006445","article-title":"Characterization of human cytochrome P450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine","volume":"3","author":"W\u00f3jcikowski","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2014.05.005_bib0140","first-page":"465","article-title":"Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes","volume":"57","author":"Rodrigues","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0145","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0090-9556(24)14947-1","article-title":"Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs","volume":"27","author":"Nakajima","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2014.05.005_bib0150","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0090-9556(24)13680-X","article-title":"Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches","volume":"28","author":"Venkatakrishnan","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2014.05.005_bib0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2133\/dmpk.23.87","article-title":"Intestinal first-pass metabolism of CYP3A4 substrates","volume":"23","author":"Kato","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bcp.2014.05.005_bib0160","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cpt1976194435","article-title":"Pharmacokinetics of methotrimeprazime after single and multiple doses","volume":"19","author":"Dahl","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2014.05.005_bib0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/17425255.1.2.203","article-title":"The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms","volume":"1","author":"Daniel","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl. 9","key":"10.1016\/j.bcp.2014.05.005_bib0170","first-page":"42","article-title":"Combined treatment strategies in psychiatry","volume":"54","author":"Nelson","year":"1993","journal-title":"J Clin. Psychiatr"},{"key":"10.1016\/j.bcp.2014.05.005_bib0175","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF02244982","article-title":"Pharmacologic treatment of schizoaffective disorder","volume":"114","author":"Keck","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2014.05.005_bib0180","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0006-2952(93)90272-X","article-title":"Fluvoxamine is a potent inhibitor of cytochrome P4501A2","volume":"45","author":"Br\u00f8sen","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s002280050163","article-title":"Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine","volume":"51","author":"Jeppesen","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0190","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.pra.0000364285.55586.ad","article-title":"Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine","volume":"16","author":"Strack","year":"2009","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.bcp.2014.05.005_bib0195","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2165\/00003088-198106060-00003","article-title":"Interaction of chlorpromazine and nortryptyline in patients with schizophrenia","volume":"6","author":"Loga","year":"1981","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bcp.2014.05.005_bib0200","first-page":"431","article-title":"Pharmacokinetics of phenothiazine neuroleptics after coadministration of carbamazepine","volume":"50","author":"Daniel","year":"1998","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0924-977X(99)00006-1","article-title":"The influence of selective serotonin reuptake inhibitors (SSRIs) on the plasma and brain pharmacokinetics of the simplest neuroleptic promazine in the rat","volume":"9","author":"Daniel","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjp.0703540","article-title":"Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants","volume":"131","author":"Daniel","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0215","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1211\/0022357011775749","article-title":"The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat","volume":"53","author":"Daniel","year":"2001","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.005_bib0220","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogenes and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2014.05.005_bib0225","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo drug metabolism in human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat Rev Drug Discov"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214002664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214002664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T23:13:06Z","timestamp":1746227586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295214002664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0006295214002664"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2014.05.005","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2014.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}